OncoMune validates Boris’s role in cancer cell death
The experiments performed used a process called RNA interference (RNAi) to specifically ‘silence’ the expression of Boris in cancer cells. The results demonstrated that the cancer cells in
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).